Upcoming event

Tags

Show all

Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens

BJU Int., July 2019

Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer

European Urology, June 2019

Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the international multicentre retrospective CATS database

European Urology Oncology, Volume 1, Issue 6, December 2018, Pages 467-475

Risk of metastatic disease on 68Ga‐PSMA PET/CT scan for primary staging of 1253 men at the diagnosis of prostate cancer

BJU International, May 2019

Head-to-head comparison of TRUS prostate biopsy vs multiparametric prostate resonance imaging with subsequent MR-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: A large prospective multicenter clinical study

European Urology

Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study

The LANCET Oncology 2018 Nov 20, Volume 20, Issue 1, Pages 100-109

Establishment of novel intraoperative monitoring and mapping method for the cavernous nerve during robot-assisted radical prostatectomy: Results of the phase I/II, first-in-human, feasibility Study

European Urology 2019 May 15

Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients

June 2019

Patient-reported quality of life following stereotactic body radiotherapy and conventionally fractionated external beam radiotherapy compared with active surveillance among men with localized prostate cancer

European Urology, February 2019

Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC)

May 2019

Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475)

May 2019

Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer

European Urology Oncology, Volume 1, Issue 1, May 2018, Pages 78-82

Next